Progression of Treating Alzheimer’s Disease with Stem Cell-based Therapies

  • Jigishu Ahmed International Centre for Diarrhoeal Disease Research, Bangladesh (icddrb)
  • Hafizur Rahman Department of Clinical Hematology and Cancer Biology, International Centre for Diarrhoeal Disease Research, Bangladesh (icddrb)

Abstract

Alzheimer’s disease is one form of dementia affecting a significant proportion of the population. The etiology of this prevalent disease is currently unknown. It is postulated that AD can be treated by using stem cell-based therapies by replacing the lost neurons in the atrophic regions of the brain. For these novel therapies to be successful several sources of stem cells have been proposed, such as pluripotent stem cells as well as multipotent stem cells. Proof of concept in animal studies have shown that stem cells can grafted into the affected regions or delivered intravenously into affected parts of the brain. These experiments had improved cognition and memory performance in rodents. The promising results seen in animal models have increased interest in conducting clinical trials using the same technique. In the last 5 years, several treatments have reached phase II clinical trials.  

Keywords: Alzheimer’s disease, dementia, neurodegenerative disease, stem cell based-therapies, stem cell-based treatments, stem cells

Downloads

Download data is not yet available.

References


  1. Association∗, “2019 Alzheimer’s disease facts and figures,” Alzheimer’s Dementia, vol. 15, no. 3, pp. 321–387, 2019.

  2. Xu, S. L. Murphy, K. D. Kochanek, and B. A. Bastian, “Deaths: Final Data for 2013.,” National Vital Statistics Reports Centers Dis Control Prev National Cent Heal Statistics National Vital Statistics Syst, vol. 64, no. 2, pp. 1–119, 2016.

  3. Burns and S. Iliffe, “Alzheimer’s disease,” Bmj, vol. 338, no. feb05 1, p. b158, 2009.

  4. Campion et al., “Early-Onset Autosomal Dominant Alzheimer Disease: Prevalence, Genetic Heterogeneity, and Mutation Spectrum,” Am J Hum Genetics, vol. 65, no. 3, pp. 664–670, 1999.

  5. Priller, T. Bauer, G. Mitteregger, B. Krebs, H. A. Kretzschmar, and J. Herms, “Synapse Formation and Function Is Modulated by the Amyloid Precursor Protein,” J Neurosci, vol. 26, no. 27, pp. 7212–7221, 2006.

  6. Zheng and E. H. Koo, “The amyloid precursor protein: beyond amyloid,” Mol Neurodegener, vol. 1, no. 1, p. 5, 2006.

  7. Arispe, E. Rojas, and H. Pollard, “Alzheimer disease amyloid beta protein forms calcium channels in bilayer membranes: blockade by tromethamine and aluminum.,” Proc National Acad Sci, vol. 90, no. 2, pp. 567–571, 1993.

  8. Y. Abramov, L. Canevari, and M. R. Duchen, “Calcium signals induced by amyloid β peptide and their consequences in neurons and astrocytes in culture,” Biochimica Et Biophysica Acta Bba - Mol Cell Res, vol. 1742, no. 1–3, pp. 81–87, 2004.

  9. raiswamy et al., “Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study,” Mol Psychiatr, vol. 19, no. 9, p. 1044, 2014.

  10. Gilman et al., “Clinical effects of A&bgr; immunization (AN1792) in patients with AD in an interrupted trial,” Neurology, vol. 64, no. 9, pp. 1553–1562, 2005.

  11. G. Hunsberger et al., “Accelerating stem cell trials for Alzheimer’s disease,” Lancet Neurology, vol. 15, no. 2, pp. 219–230, 2016.

  12. F. Egan et al., “Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease,” New Engl J Med, vol. 380, no. 15, pp. 1408–1420, 2019.

  13. Sevigny et al., “The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease,” Nature, vol. 537, no. 7618, p. 50, 2016.

  14. E. Reubinoff, M. F. Pera, C.-Y. Fong, A. Trounson, and A. Bongso, “Embryonic stem cell lines from human blastocysts: somatic differentiation in vitro,” Nat Biotechnol, vol. 18, no. 4, p. nbt0400_399, 2000.

  15. Evans and M. Kaufman, “Establishment in culture of pluripotential cells from mouse embryos,” Nature, vol. 292, no. 5819, p. 292154a0, 1981.

  16. Martin, “Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells,” Proc National Acad Sci, vol. 78, no. 12, pp. 7634–7638, 1981.

  17. Wobus, R. Grosse, and J. Schöneich, “Specific effects of nerve growth factor on the differentiation pattern of mouse embryonic stem cells in vitro.,” Biomed Biochim Acta, vol. 47, no. 12, pp. 965–73, 1988.

  18. Bain, D. Kitchens, M. Yao, J. E. Huettner, and D. I. Gottlieb, “Embryonic Stem Cells Express Neuronal Properties in Vitro,” Dev Biol, vol. 168, no. 2, pp. 342–357, 1995.

  19. Okabe, K. Forsberg-Nilsson, C. A. Spiro, M. Segal, and R. McKay, “Development of neuronal precursor cells and functional postmitotic neurons from embryonic stem cells in vitro,” Mech Develop, vol. 59, no. 1, pp. 89–102, 1996.

  20. Gaspard, T. Bouschet, A. Herpoel, G. Naeije, J. van den Ameele, and P. Vanderhaeghen, “Generation of cortical neurons from mouse embryonic stem cells,” Nat Protoc, vol. 4, no. 10, p. nprot.2009.157, 2009.

  21. Takahashi and S. Yamanaka, “Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors,” Cell, vol. 126, no. 4, pp. 663–676, 2006.

  22. Stadtfeld, M. Nagaya, J. Utikal, G. Weir, and K. Hochedlinger, “Induced Pluripotent Stem Cells Generated Without Viral Integration,” Science, vol. 322, no. 5903, pp. 945–949, 2008.

  23. Seki et al., “Generation of Induced Pluripotent Stem Cells from Human Terminally Differentiated Circulating T Cells,” Cell Stem Cell, vol. 7, no. 1, pp. 11–14, 2010.

  24. M. Chambers, C. A. Fasano, E. P. Papapetrou, M. Tomishima, M. Sadelain, and L. Studer, “Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling,” Nat Biotechnol, vol. 27, no. 3, p. nbt.1529, 2009.

  25. Liu et al., “Direct reprogramming of human fibroblasts into dopaminergic neuron-like cells,” Cell Res, vol. 22, no. 2, p. cr2011181, 2011.

  26. Doetsch, I. Caillé, D. A. Lim, J. García-Verdugo, and A. Alvarez-Buylla, “Subventricular Zone Astrocytes Are Neural Stem Cells in the Adult Mammalian Brain,” Cell, vol. 97, no. 6, pp. 703–716, 1999.

  27. L. Spalding et al., “Dynamics of Hippocampal Neurogenesis in Adult Humans,” Cell, vol. 153, no. 6, pp. 1219–1227, 2013.

  28. Kim, T. Son, K. Kim, H. Park, M. P. Mattson, and J. Lee, “Interferon-γ Promotes Differentiation of Neural Progenitor Cells via the JNK Pathway,” Neurochem Res, vol. 32, no. 8, pp. 1399–1406, 2007.

  29. Li, K. Tsang, S. Choi, K. Li, P. Shaw, and K. Lau, “Neuronal Differentiation of C17.2 Neural Stem Cells Induced by a Natural Flavonoid, Baicalin,” Chembiochem, vol. 12, no. 3, pp. 449–456, 2011.

  30. Friedenstein, I. Piatetzky-Shapiro, and K. Petrakova, “Osteogenesis in transplants of bone marrow cells.,” J Embryol Exp Morph, vol. 16, no. 3, pp. 381–90, 1966.

  31. . Goodwin et al., “Multilineage differentiation activity by cells isolated from umbilical cord blood: Expression of bone, fat, and neural markers,” Biol Blood Marrow Tr, vol. 7, no. 11, pp. 581–588, 2001.

  32. Igura, X. Zhang, K. Takahashi, A. Mitsuru, S. Yamaguchi, and T. A. Takahashi, “Isolation and characterization of mesenchymal progenitor cells from chorionic villi of human placenta,” Cytotherapy, vol. 6, no. 6, pp. 543–553, 2004.

  33. M. Gimble, A. J. Katz, and B. A. Bunnell, “Adipose-Derived Stem Cells for Regenerative Medicine,” Circ Res, vol. 100, no. 9, pp. 1249–1260, 2007.

  34. Kern, H. Eichler, J. Stoeve, H. Klüter, and K. Bieback, “Comparative Analysis of Mesenchymal Stem Cells from Bone Marrow, Umbilical Cord Blood, or Adipose Tissue,” Stem Cells, vol. 24, no. 5, pp. 1294–1301, 2006.

  35. Woodbury, E. J. Schwarz, D. J. Prockop, and I. B. Black, “Adult rat and human bone marrow stromal cells differentiate into neurons,” J Neurosci Res, vol. 61, no. 4, pp. 364–370, 2000.

  36. Duncan and M. Valenzuela, “Alzheimer’s disease, dementia, and stem cell therapy,” Stem Cell Res Ther, vol. 8, no. 1, p. 111, 2017.

  37. Yue et al., “ESC-Derived Basal Forebrain Cholinergic Neurons Ameliorate the Cognitive Symptoms Associated with Alzheimer’s Disease in Mouse Models,” Stem Cell Rep, vol. 5, no. 5, pp. 776–790, 2015.

  38. M. Salem, H. H. Ahmed, H. M. Atta, M. A. Ghazy, and H. A. Aglan, “Potential of bone marrow mesenchymal stem cells in management of Alzheimer’s disease in female rats,” Cell Biol Int, vol. 38, no. 12, pp. 1367–1383, 2014.

  39. Park et al., “Human adipose tissue‐derived mesenchymal stem cells improve cognitive function and physical activity in ageing mice,” J Neurosci Res, vol. 91, no. 5, pp. 660–670, 2013.

  40. Shin et al., “Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models,” Autophagy, vol. 10, no. 1, pp. 32–44, 2013.

  41. Kim et al., “Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer’s disease dementia: A phase 1 clinical trial,” Alzheimer’s Dementia Transl Res Clin Interventions, vol. 1, no. 2, pp. 95–102, 2015.

  42. Davies, N. Horwood, S. Isaacs, and D. Mann, “The effect of age and Alzheimer’s disease on pyramidal neuron density in the individual fields of the hippocampal formation,” Acta Neuropathol, vol. 83, no. 5, pp. 510–517, 1992.

  43. -J. Swijnenburg et al., “Immunosuppressive therapy mitigates immunological rejection of human embryonic stem cell xenografts,” Proc National Acad Sci, vol. 105, no. 35, pp. 12991–12996, 2008.

  44. Bhutani et al., “Whole-genome mutational burden analysis of three pluripotency induction methods,” Nat Commun, vol. 7, no. 1, p. 10536, 2016.

Published
2019-07-28
How to Cite
[1]
J. Ahmed and H. Rahman, “Progression of Treating Alzheimer’s Disease with Stem Cell-based Therapies”, Int. Ann. Sci., vol. 8, no. 1, pp. 38-46, Jul. 2019.
Section
Review Article